This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of targeted NSAEs
Timeframe: 15 Years
Frequency of targeted NSAEs
Timeframe: 15 Years
Duration of targeted NSAEs
Timeframe: 15 Years
Outcome of targeted NSAEs
Timeframe: 15 Years
Incidence of AESIs
Timeframe: 15 Years
Frequency of AESIs
Timeframe: 15 Years
Duration of AESIs
Timeframe: 15 Years
Outcome of AESIs
Timeframe: 15 Years
Incidence of targeted SAEs
Timeframe: 15 Years
Frequency of targeted SAEs
Timeframe: 15 Years
Duration of targeted SAEs
Timeframe: 15 Years
Outcome of targeted SAEs
Timeframe: 15 Years
Incidence of AEs related to IP leading to death
Timeframe: 15 Years